Novartis Leads Late-Stage Trials Targeting Genetic Heart-Risk Factor Lp(a)
Drug makers are moving experimental therapies for the genetically driven cholesterol particle Lp(a) into late-stage studies, eyeing a multi-billion-dollar market.
A sizable portion of the population carries elevated Lp(a), a hereditary risk factor for heart attacks that cannot be mitigated by lifestyle changes. Companies, with Novartis at the forefront, are now testing new drugs aimed at lowering these levels in advanced clinical trials. Success could open a lucrative market, as current options to address Lp(a) are limited. The effort reflects both a medical need and a commercial opportunity worth billions.
Why it matters
New drugs could lower a genetic heart-risk factor that currently has no effective treatment, impacting millions and creating a huge market.
In this story
